DOCSLIB.ORG

Sleeping Sickness)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sleeping Sickness) NEUROLOGICAL PROGRESS The Continuing Problem of Human African Trypanosomiasis (Sleeping Sickness) Peter G. E. Kennedy, MD, PhD, DSc Human African trypanosomiasis, also known as sleeping sickness, is a neglected disease, and it continues to pose a major threat to 60 million people in 36 countries in sub-Saharan Africa. Transmitted by the bite of the tsetse fly, the disease is caused by protozoan parasites of the genus Trypanosoma and comes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rhodesiense and the West African form caused by Trypanosoma brucei gambiense. There is an early or hemo- lymphatic stage and a late or encephalitic stage, when the parasites cross the blood–brain barrier to invade the central nervous system. Two critical current issues are disease staging and drug therapy, especially for late-stage disease. Lumbar puncture to analyze cerebrospinal fluid will remain the only method of disease staging until reliable noninvasive methods are developed, but there is no widespread consensus as to what exactly defines biologically central nervous system disease or what specific cerebro- spinal fluid findings should justify drug therapy for late-stage involvement. All four main drugs used for human African trypano- somiasis are toxic, and melarsoprol, the only drug that is effective for both types of central nervous system disease, is so toxic that it kills 5% of patients who receive it. Eflornithine, alone or combined with nifurtimox, is being used increasingly as first-line therapy for gambiense disease. There is a pressing need for an effective, safe oral drug for both stages of the disease, but this will require a significant increase in investment for new drug discovery from Western governments and the pharmaceutical industry. Ann Neurol 2008;64:116–127 Human African trypanosomiasis (HAT), which is also tracellular form in the host. There are two forms of the known as sleeping sickness, is one of the “neglected human disease, the East African variant caused by diseases,” a group that includes visceral leishmaniasis, Trypanosoma brucei rhodesiense and the West African schistosomiasis, and Chagas’ disease.1 Although these form caused by Trypanosoma brucei gambiense3 (Fig 1). diseases kill or disable hundreds of thousands of people If untreated, the disease is always fatal. Transmission of in underdeveloped tropical regions, current treatment the disease in both humans and cattle is by the bite of for them is often antiquated, highly toxic, and fre- the blood-sucking tsetse fly of the Glossina species.4 In- quently ineffective. The pharmaceutical industry and festation by the tsetse fly covers 10 million square ki- Western governments have until recently shown little lometers, one third of Africa’s landmass, which is an interest in developing new drugs for these diseases be- area slightly larger than the United States.1 African an- cause this is associated with little or no prospect of imal trypanosomiasis, important in domestic livestock generating significant short- or long-term financial such as cattle that suffer from a wasting disease called gain. Although there has been an entirely understand- nagana, as well as wild animals, was first shown to be able emphasis in recent times on combating such caused by Trypanosoma brucei by David Bruce in 1899 global killers as malaria, acquired immune deficiency while investigating a major outbreak of nagana in Zu- syndrome, and tuberculosis, it should be appreciated luland.5,6 Subsequent work by Aldo Castellani enabled that HAT is a major threat to the health of 60 million the identification of trypanosomes in the blood and ce- people in 36 countries in sub-Saharan Africa.2 More- rebrospinal fluid (CSF) in human patients with HAT over, HAT is the world’s third most important para- in 1903,6,7 and parasites causing the two human dis- sitic disease affecting human health after malaria and ease variants were identified during the period 1902 to schistosomiasis, as defined by the global burden of par- 1910.6 Both animals and humans can act as reservoirs asitic disease, calculated as the disability adjusted life of parasites capable of causing the human disease, but years lost.1 the detailed mechanisms by which this occurs are not HAT is caused by protozoan parasites of the genus fully understood. Animal trypanosomiasis has a major Trypanosoma, single-celled organisms that remain in ex- human and economic impact because it adversely af- From the Department of Neurology, Division of Clinical Neuro- Published online in Wiley InterScience (www.interscience.wiley.com). sciences, Faculty of Medicine, University of Glasgow Institute of DOI: 10.1002/ana.21429 Neurological Sciences, Southern General Hospital, Glasgow, GS1, 4TF, Scotland, UK. Address correspondence to Dr Kennedy, Southern General Hospi- tal, Glasgow G51 4TF, United Kingdom. Received Mar 11, 2008, and in revised form Apr 23. Accepted for publication May 1, 2008. E-mail: [email protected] 116 Published 2008 by Wiley-Liss, Inc., through Wiley Subscription Services Outline of Parasite-Host Biology Details of parasite-host biology have been given else- where.3,4 Although animals are the main reservoir for T.b. rhodesiense parasites, humans are the main reser- voir for T.b. gambiense parasites.1,4 In brief, the tsetse fly vector feeds on an infected animal or human, after which the ingested trypanosomes undergo a number of biochemical and structural alterations in the fly’s mid- gut. Infective forms of the trypanosome then reach the fly’s salivary glands from which they are transmitted to the human host through biting. A fly remains infective for life, and the whole infective cycle is probably com- pleted successfully in only 1 in 10 flies.4 Approximately 5 to 15 days after infection, a painful skin lesion called a trypanosomal chancre may develop at the site of the bite.4 The parasites spread in the host bloodstream 1 to 3 weeks after the initial bite, and invade the lymph nodes and systemic organs including the liver, spleen, heart, endocrine system, and eyes in what is termed the early, stage 1, or hemolymphatic stage.3,4 If untreated, within a few weeks in the case of rhodesiense infection, Fig 1. Distribution of East and West African sleeping sickness or many months in the case of gambiense infection, the in sub-Saharan Africa. Green areas represent Trypanosoma parasites will cross the blood–brain barrier (BBB) and brucei gambiense infection; brown areas represent Trypano- enter the central nervous system (CNS), which marks 4,13 soma brucei rhodesiense infection. (Modified from Atouguia the late, stage 2, or encephalitic stage of the disease. and Kennedy.) The entire tempo of the disease is faster in the more aggressive rhodesiense infection compared with the fects livestock production and farming. During the first chronic gambiense infection, probably as a result of the half of the twentieth century, HAT caused by T.b. greater adaptation of the latter parasite to the host.1,3 gambiense decimated entire communities in central Af- Much is known about the molecular biology of the rica,8 but then the disease was almost brought under trypanosome, and the entire T. brucei genome was se- control during the 1960s primarily as a result of highly quenced in 2005.14 It has about 9,000 genes, about effective surveillance programs. But HAT then quickly 10% of which are variable surface glycoprotein (VSG) reemerged with a progressive increase in the numbers genes encoding the VSG that are distributed on the of new cases and deaths. The World Health Organiza- entire surface of the trypanosome.3 During infection, tion (WHO) provided estimates during the period the trypanosome is able to rapidly switch the expres- 1986 to 2004 about the disease that have been widely sion of the VSG genes in and out of the expression quoted, with an annual prevalence of 300,000 to site, the result of which is antigenic variation in which 500,000 cases.2,9,10 Factors causing this increase were the surface VSG genes change so fast that the parasite primarily war and famine, which resulted in severe dis- is able to constantly evade the host’s immune re- ruption of disease surveillance and treatment, especially sponse.15 For this reason, it has not been possible, so in Uganda, Angola, Sudan, and the Congos where the far, to develop a vaccine for HAT. disease occurred in epidemics.11 Although it is still dif- ficult to provide accurate estimates of disease incidence Clinical Features of the Disease and prevalence, more recent WHO estimates have sug- There is seldom a clear clinical distinction between the gested that as a result of more efficient surveillance, a early and late stages of HAT that may appear to run significant improvement has occurred with currently as into each other. Patients in the early, or hemolym- low as 70,000 existing cases, mainly infected with T.b- phatic, stage may report nonspecific symptoms such as .gambiense.10 However, HAT has already demonstrated malaise, headache, weight loss, arthralgia, and fatigue, its ability to recur even after it had been virtually and also have episodes of fever accompanied by rigors brought under control. About 50 cases of HAT occur and vomiting, which may be misdiagnosed as malar- annually outside of Africa,12 usually as a result of ia.13,16 There may also be generalized lymphadenopa- Western travelers returning to North America or Eu- thy, and enlargement of posterior cervical lymph nodes rope from the East African game reserves; therefore, all is typical of gambiense disease (“Winterbottom’s sign”). physicians need to be aware of the key features of the Other symptoms and signs may correspond to partic- disease and its most appropriate drug therapy. ular organ involvement. Thus, there may be several dif- Kennedy: Human African Trypanosomiasis 117 ferent kinds of skin rash, as well as pruritus, especially Table 1.
Load more

Recommended publications
  • Visceral Leishmaniasis (Kala-Azar) and Malaria Coinfection in an Immigrant in the State of Terengganu, Malaysia: a Case Report
    Journal of Microbiology, Immunology and Infection (2011) 44,72e76 available at www.sciencedirect.com journal homepage: www.e-jmii.com CASE REPORT Visceral leishmaniasis (kala-azar) and malaria coinfection in an immigrant in the state of Terengganu, Malaysia: A case report Ahmad Kashfi Ab Rahman a,*, Fatimah Haslina Abdullah b a Infectious Disease Clinic, Department of Medicine, Hospital Sultanah Nur Zahirah, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia b Microbiology Unit, Department of Pathology, Hospital Sultanah Nur Zahirah, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia Received 28 April 2009; received in revised form 30 July 2009; accepted 30 November 2009 KEYWORDS Malaria is endemic in Malaysia. Leishmaniasis is a protozoan infection rarely reported in Amphotericin B; Malaysia. Here, a 24-year-old Nepalese man who presented with prolonged fever and he- Coinfection; patosplenomegaly is reported. Blood film examination confirmed a Plasmodium vivax ma- Leishmaniasis; laria infection. Despite being adequately treated for malaria, his fever persisted. Bone Malaria; marrow examination showed presence of Leishman-Donovan complex. He was success- Treatment fully treated with prolonged course of amphotericin B. The case highlights the impor- tance of awareness among the treating physicians of this disease occurring in a foreign national from an endemic region when he presents with fever and hepatosplenomegaly. Coinfection with malaria can occur although it is rare. It can cause significant delay of the diagnosis of leishmaniasis. Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved. Introduction leishmaniasis is not. Malaysia is considered free of endemic Leishmania species although few species of Malaysian sandflies have been described, possibly because the sand- Malaysia is a tropical country and located in the region of 1,3 Southeast Asia.
    [Show full text]
  • Autophagy in Trypanosomatids
    Cells 2012, 1, 346-371; doi:10.3390/cells1030346 OPEN ACCESS cells ISSN 2073-4409 www.mdpi.com/journal/cells Review Autophagy in Trypanosomatids Ana Brennand 1,†, Eva Rico 2,†,‡ and Paul A. M. Michels 1,* 1 Research Unit for Tropical Diseases, de Duve Institute, Université catholique de Louvain, Avenue Hippocrate 74, postal box B1.74.01, B-1200 Brussels, Belgium; E-Mail: [email protected] 2 Department of Biochemistry and Molecular Biology, University Campus, University of Alcalá, Alcalá de Henares, Madrid, 28871, Spain; E-Mail: [email protected] † These authors contributed equally to this work. ‡ Present Address: Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, King’s Buildings, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, UK. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +32-2-7647473; Fax: +32-2-7626853. Received: 28 June 2012; in revised form: 14 July 2012 / Accepted: 16 July 2012 / Published: 27 July 2012 Abstract: Autophagy is a ubiquitous eukaryotic process that also occurs in trypanosomatid parasites, protist organisms belonging to the supergroup Excavata, distinct from the supergroup Opistokontha that includes mammals and fungi. Half of the known yeast and mammalian AuTophaGy (ATG) proteins were detected in trypanosomatids, although with low sequence conservation. Trypanosomatids such as Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are responsible for serious tropical diseases in humans. The parasites are transmitted by insects and, consequently, have a complicated life cycle during which they undergo dramatic morphological and metabolic transformations to adapt to the different environments.
    [Show full text]
  • History of Kala-Azar Is Older Than the Dated Records
    Professor C. P. Thakur, MD, FRCP (London & Edin.) Emeritus Professor of Medicine, Patna Medical College Member of Parliament, Former Union Minister of Health, Government of India Chairman, Balaji Utthan Sansthan, Uma Complex, Fraser Road – Patna-800 001, Bihar. Tel.: +91-0612-2221797, Fax:+91-0612-2239423 Email: [email protected], [email protected], [email protected] Website: www.bus.org.in “History of kala-azar is older than the dated records. In those days malaria was very common and some epidemics of kala-azar were passed as toxic malaria. Twining writing in 1835 described a condition that he called “endemic cachexia of the tropical counties that are subject to paludal exhalations”. The disease remained unrecognized for a faily long time but the searching nature of human mind could come to a final diagnosis, though many aspects of the disease are still unexplored” • Leishmaniasis Cachexial Fever • Internal Catechetic fever leishmaniasis Dum-Dum Fever • Visceral Burdwan Fever leishmaniasis Sirkari Disease • General Sahib’s disease leishmaniasis Kala-dukh • Kala-azar of Kala-jwar adults Kala-hazar • Indian kala-azar Assam fever • Black Fever Leishman-Donovan Disease • Black Sickness Infantile Kala-azar (Nicolle) • Tropical leishmaniasis Infantile leishmaniasis • Tropical cachexia Mediterranean Kala-azar • Tropical Kala-azar Mediterranean leishmaniasis • Tropical Febrile splenic Anaemia (Fede) Splenomegaly Anaemia infantum a leishmania • Non-malarial (Pianese) remittent fever Leishmania anaemia (Jemme • Malaria Cachexia (in error)
    [Show full text]
  • Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity
    microorganisms Review Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity John M. Curtin 1,2,* and Naomi E. Aronson 2 1 Infectious Diseases Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA 2 Infectious Diseases Division, Uniformed Services University, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-011-301-295-6400 Abstract: Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers. Clinical presentations may include asymptomatic and symptomatic visceral leishmaniasis (so-called Kala-azar), as well as cutaneous or mucosal disease. Although cutaneous leishmaniasis (caused by Leishmania mexicana in the United States) is endemic in some southwest states, other causes for concern include reactivation of imported visceral leishmaniasis remotely in time from the initial infection, and the possible long-term complications of chronic inflammation from asymptomatic infection. Climate change, the identification of competent vectors and reservoirs, a highly mobile populace, significant population groups with proven exposure history, HIV, and widespread use of immunosuppressive medications and organ transplant all create the potential for increased frequency of leishmaniasis in the U.S. Together, these factors could contribute to leishmaniasis emerging as a health threat in the U.S., including the possibility of sustained autochthonous spread of newly introduced visceral disease. We summarize recent data examining the epidemiology and major risk factors for acquisition of cutaneous and visceral leishmaniasis, with a special focus on Citation: Curtin, J.M.; Aronson, N.E.
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Visceral Leishmaniasis: a Global Overview
    J Glob Health Sci. 2020 Jun;2(1):e3 https://doi.org/10.35500/jghs.2020.2.e3 pISSN 2671-6925·eISSN 2671-6933 Review Article Visceral leishmaniasis: a global overview Richard G. Wamai ,1 Jorja Kahn ,2 Jamie McGloin ,3 Galen Ziaggi 3 1Department of Cultures, Societies and Global Studies, Northeastern University, College of Social Sciences and Humanities, Integrated Initiative for Global Health, Boston, MA, USA 2Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA 3Department of Health Sciences, Northeastern University, Bouvé College of Health Science, Boston, MA, USA Received: Feb 1, 2020 ABSTRACT Accepted: Mar 14, 2020 Correspondence to The leishmaniases are protozoan infections that are among the neglected tropical diseases Richard G. Wamai (NTDs). Over one billion people are at risk of these diseases in virtually all continents. Department of Cultures, Societies and Global These diseases debilitate large numbers of people, keeping them from full, productive lives. Studies, Northeastern University, College of Visceral leishmaniasis (VL) is the most severe form of these diseases, killing more people Social Sciences and Humanities, Integrated Initiative for Global Health, 360 Huntington than any other parasitic disease except malaria. About 90% of the global burden for VL is Ave., Boston, MA 02115, USA. found in just 7 countries, 4 of which are in Eastern Africa (Sudan, South Sudan, Ethiopia E-mail: [email protected] and Kenya), 2 in Southeast Asia (India, Bangladesh) and Brazil, which carries nearly all of cases in South America. In 2005 the World Health Organization launched a strategy to © 2020 Korean Society of Global Health.
    [Show full text]
  • Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in South Sudan
    Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in South Sudan Acromyns DAT Direct agglutination test FDA Freeze – dried antigen IM Intramuscular IV Intravenous KA Kala–azar ME Mercaptoethanol ORS Oral rehydration salt PKDL Post kala–azar dermal leishmaniasis RBC Red blood cells RDT Rapid diagnostic test RR Respiratory rate SSG Sodium stibogluconate TFC Therapeutic feeding centre TOC Test of cure VL Visceral leishmaniasis WBC White blood cells WHO World Health Organization Table of contents Acronyms ...................................................................................................................................... 2 Acknowledgements ....................................................................................................................... 4 Foreword ...................................................................................................................................... 5 1. Introduction ........................................................................................................................... 7 1.1 Background information ............................................................................................... 7 1.2 Lifecycle and transmission patterns ............................................................................. 7 1.3 Human infection and disease ....................................................................................... 8 2. Diagnosis ..............................................................................................................................
    [Show full text]
  • COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print
    COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • Visceral Leishmaniasis in the Developing World
    Visceral Leishmaniasis in the Developing World Gilead Sciences is committed to supporting global efforts to control and eliminate visceral leishmaniasis (VL), a parasitic infectious disease that predominantly affects people in developing world countries. AmBisome® is a World Health Organization (WHO)-preferred treatment for VL in most endemic regions,1 and Gilead undertakes a number of activities to expand global access to this therapy for patients in need. Snapshot • Visceral leishmaniasis (VL) is • Since 1992, Gilead has • Gilead is donating the world’s second-deadliest provided AmBisome®, 445,000 vials of AmBisome parasitic disease, after malaria.1 a preferred treatment for VL, to the World Health at no-profit prices. Organization over 5 years.2 and, in a recent study in India, this regimen was shown VL: A Deadly Disease in the to be significantly more cost-effective than conventional Developing World amphotericin B-containing treatment regimens.5 VL is the world’s second-deadliest parasitic Gilead has worked since 1992 to increase access to VL disease after malaria, with 400,000 cases and treatment by providing AmBisome to public sector agencies, 40,000 deaths occuring annually.1,3 It is caused by several including WHO, at no-profit prices. In December 2011, Gilead species of the Leishmania parasite, which are transmitted signed a new agreement with WHO to donate 445,000 vials to humans through the bite of infected female sandflies. of AmBisome over five years to treat VL in countries including Without treatment, VL is nearly always fatal.3 Bangladesh, Ethiopia, South Sudan and Sudan. The donation will provide treatment for more than 50,000 patients.2 Most VL cases worldwide affect children and young adults.
    [Show full text]
  • The Battle Is Not Over Until It Is Won
    HUMAN AFRICAN TRYPANOSOMIASIS SLEEPING SICKNESS The battle is not over until it is won Sleeping sickness, or human African trypa- melarsoprol. The latter, however, is still the nosomiasis, threatens millions of people in first-line treatment for the less commonT.b. 36 countries across sub-Saharan Africa. The rhodesiense HAT. Democratic Republic of the Congo bears the To contribute to the WHO elimination goal, a brunt, accounting for 83% of all cases. In the ‘test and treat’ strategy that would be imple- 1960s there were less than 5,000 patients mented at the primary healthcare level is on suffering from the disease in the whole of the the horizon, with potential simple oral pills continent. However, the end of the 20th cen- for both the early and late stage as well as tury – with internal conflict, competing health both types of HAT, that are currently in devel- priorities, and decolonization – witnessed a opment, along with new rapid diagnostics, halt in the successful control methods, and which together would remove the need for the number of cases reported rose painful and dangerous lumbar punc- steeply, peaking in 1998 with tures. This would mean that rural over 37,000 cases reported in health centres, rather than hos- that year. Nowadays, thanks pitals, will play an increasingly to the combined efforts of important role, especially as the WHO, National Sleeping number of reported cases con- Sickness Control Pro- tinues to dwindle. grammes, NGOs and other partners, the disease has once more been brought under control, and since 2010 the number of reported cases has fallen below 8,000.
    [Show full text]
  • Program and Abstracts
    Seventy 2019 years of Soixante-dix AU/ISCTRC Années de 1949 l’UA / CSIRLT 35TH GENERAL CONFERENCE OF THE INTERNATIONAL SCIENTIFIC COUNCIL FOR TRYPANOSOMIASIS RESEARCH AND CONTROL (ISCTRC) AND 18TH PATTEC NATIONAL COORDINATORS MEETING PROGRAMME AND ABSTRACTS BOOK 35TH GENERAL CONFERENCE OF THE INTERNATIONAL SCIENTIFIC COUNCIL FOR TRYPANOSOMIASIS RESEARCH AND CONTROL (ISCTRC) AND 18TH PATTEC NATIONAL COORDINATORS MEETING PROGRAMME AND ABSTRACTS BOOK ABOUT THE CONFERENCE Theme of the Conference Impact of African Trypanosomiasis on Human and Animal Health, Sustainable Agriculture and Rural Development in the face of challenges to sustainable investment in AAT control and HAT elimination”Members of the Scientific Committee The members of the 35th ISCTRC Scientific Committee that were appointed by the Director of AU-IBAR were drawn from various institutions working on Tsetse and Trypanosomiasis. The committee received and considered 140 abstracts addressing the various sub- themes of the conference. Prof. Ahmed Elsawalhy, Director of AU-IBAR, Chairperson Dr. James Wabacha, ISCTRC Secretary, Member Dr. Gift Wanda, Member Dr. Daniel Masiga, Member Dr. Jose Ramon Franco Rapporteur and Moderators Rapporteur General Grace Mulira Deputy Rapporteur General Njelembo Mbewe Moderators and rapporteurs for the various thematic sessions are as per the programme Presentation guidelines Allocated time for presentations: Each presentation will be allocated 10 minutes and 5 minutes for discussion. Viewing of posters There will be continuous viewing of the posters. The presenters for the posters will be at the stands during the coffee/tea breaks. There will be general discussion on the posters in the plenary on Thursday, 26th September 2019. Uploading of presentations in the conference computer Presenters who will be making presentation during the first day are IV requested to upload their presentation during registration on Sunday.
    [Show full text]